EUVIMEDEUVIMED entdecken
Crossref

The ‘ABC’ of split-nanoluciferase HIF heterodimerization bioassays: Applications, Benefits & Considerations

Liesl K Janssens, Christophe P Stove

Biochemical Pharmacology · 2024

DOI: 10.1016/j.bcp.2024.116478 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024. Verfasst von Liesl K Janssens und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, Belgium. Hauptthemen laut MEDLINE: Protein Multimerization, Hypoxia-Inducible Factor 1. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Ghent University, Partnership for Clean Competition.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypoxia-inducible factors (HIF) are interesting targets for multiple therapeutic indications. While HIF activation is desired for the treatment of anemia-related and ischemic diseases, HIF inhibition is of tremendous interest to anti-cancer drug development. Different signaling events within the HIF pathway are being targeted by drug discovery programs, with a special interest in HIF-selective (possibly also HIF1/2 isoform-selective) compounds. In this study, we applied recently developed cell-based split-nanoluciferase HIF heterodimerization assays to study the effects of compounds, targeting HIF activity by various mechanisms of action. This study shows that the application of similar or diverse assay protocols allows to detect various influences on HIF heterodimerization as a key signaling event in the oxygen sensing pathway: increased HIF heterodimerization (roxadustat, MG-132), decreased HIF heterodimerization (PX-478, ibuprofen) and direct (HIF isoform-selective) heterodimerization inhibiting effects (PT-2385). Changes in treatment time and in the assay protocol allowed to assess direct and indirect effects on HIFα-HIFβ heterodimerization. In addition to the evaluation of applications of these new bioassays regarding pharmacological characterizations, benefits and considerations are discussed related to the use of cellular, luminescent-based bioassays. Briefly, benefits include the bidirectional nature of the biological readout, the upstream mechanism of detection, the differentiation between HIF1 and HIF2 effects and the simulation of various conditions. Specific and general considerations include cell-based, technical and disease/drug-related aspects (e.g., non-specific effects, color interference). In summary, the versatility of these bioassays offers benefits in widespread applications regarding drug discovery and pharmacological characterization of various therapeutics, applying either the same or optimized experimental protocols.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein MultimerizationHypoxia-Inducible Factor 1HumansAryl Hydrocarbon Receptor Nuclear TranslocatorBasic Helix-Loop-Helix ProteinsBiological AssayHypoxia-Inducible Factor 1, alpha SubunitIsoquinolinesLuciferasesMustard CompoundsPhenylpropionatesEndothelial PAS Domain-Containing Protein 1Glycine

Stichwörter der Autor:innen

AnemiaCancerDrug developmentFunctional assayHypoxia inducible factorLuminescence

Substanzen

Aryl Hydrocarbon Receptor Nuclear TranslocatorBasic Helix-Loop-Helix ProteinsHypoxia-Inducible Factor 1, alpha SubunitIsoquinolinesLuciferasesMustard CompoundsPhenylpropionatesHypoxia-Inducible Factor 1Endothelial PAS Domain-Containing Protein 12-amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide

Autor:innen und Institutionen

  • Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, Belgium.
  • Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, Belgium. Electronic address: christophe.stove@ugent.be.

Förderung

  • Ghent University
  • Partnership for Clean Competition

Zitieren

APA

Janssens, L. K., & Stove, C. P. (2024). The ‘ABC’ of split-nanoluciferase HIF heterodimerization bioassays: Applications, Benefits & Considerations. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2024.116478

Vancouver

Janssens LK, Stove CP. The ‘ABC’ of split-nanoluciferase HIF heterodimerization bioassays: Applications, Benefits & Considerations. Biochemical Pharmacology. 2024. doi:10.1016/j.bcp.2024.116478

BibTeX
@article{Janssens2024,
  author = {Janssens, Liesl K and Stove, Christophe P},
  title = {The ‘ABC’ of split-nanoluciferase HIF heterodimerization bioassays: Applications, Benefits & Considerations},
  journal = {Biochemical Pharmacology},
  year = {2024},
  doi = {10.1016/j.bcp.2024.116478}
}
Kostenlos starten →